Chronic Periaortitis: an Update

Curr Rheumatol Rep. 2018 Nov 5;20(12):80. doi: 10.1007/s11926-018-0789-2.

Abstract

Purpose of review: We aim to review traditional concepts and recent developments on the nosology, pathophysiology, clinical phenotypes and treatment of chronic periaortitis (CP).

Recent findings: CP is a rare disorder hallmarked by a periaortic fibro-inflammatory tissue. It can present as an isolated disease, but it can also be associated with other autoimmune and fibro-inflammatory lesions (e.g., fibrosing mediastinitis, sclerosing pancreato-cholangitis) that are part of the spectrum of IgG4-related disease. In a subgroup of patients, it also involves the thoracic aorta (so-called "diffuse periaortitis"), which supports the notion of an inflammatory disorder of large arteries. The pathogenesis of CP is multifactorial: recent studies have elucidated the predisposing role of immunogenetic variants and exposures to environmental agents such as smoking and asbestos. CP is a rare immune-mediated disease that affects the abdominal aorta and the iliac arteries and, in some cases, the thoracic aorta. It may overlap with manifestations of IgG4-related disease, and its treatment comprises glucocorticoids, conventional and biological immunosuppressive agents.

Keywords: Aorta; Chronic periaortitis; Fibro-inflammatory disorder; IgG4; IgG4-related disease; Retroperitoneal fibrosis; Vasculitis.

Publication types

  • Review

MeSH terms

  • Aorta, Abdominal / immunology
  • Aorta, Abdominal / pathology*
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunoglobulin G / blood
  • Retroperitoneal Fibrosis / diagnosis*
  • Retroperitoneal Fibrosis / drug therapy
  • Retroperitoneal Fibrosis / immunology
  • Retroperitoneal Fibrosis / pathology

Substances

  • Glucocorticoids
  • Immunoglobulin G